Robert A. Parise

3.7k total citations
100 papers, 3.0k citations indexed

About

Robert A. Parise is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Robert A. Parise has authored 100 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 37 papers in Oncology and 15 papers in Hematology. Recurrent topics in Robert A. Parise's work include Cancer therapeutics and mechanisms (14 papers), Epigenetics and DNA Methylation (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Robert A. Parise is often cited by papers focused on Cancer therapeutics and mechanisms (14 papers), Epigenetics and DNA Methylation (13 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Robert A. Parise collaborates with scholars based in United States, France and Canada. Robert A. Parise's co-authors include Merrill J. Egorin, Jan H. Beumer, Julie L. Eiseman, Ramesh K. Ramanathan, Erin Joseph, Frank J. Gonzalez, Akiko Ogai, T. S. Tracy, Magang Shou and Ken Korzekwa and has published in prestigious journals such as Journal of Clinical Oncology, Immunity and Biochemistry.

In The Last Decade

Robert A. Parise

98 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert A. Parise United States	30	1.4k	1.0k	533	354	255	100	3.0k
Akinobu Hamada Japan	36	1.2k 0.8×	1.6k 1.5×	216 0.4×	351 1.0×	341 1.3×	178	3.7k
Ming Zhao United States	42	3.1k 2.2×	1.4k 1.4×	289 0.5×	401 1.1×	214 0.8×	133	5.3k
Jürgen Venitz United States	29	1.1k 0.8×	607 0.6×	178 0.3×	240 0.7×	212 0.8×	87	2.9k
Liguang Lou China	36	1.9k 1.4×	1.5k 1.5×	235 0.4×	136 0.4×	194 0.8×	135	4.0k
Ramzi M. Mohammad United States	41	2.9k 2.1×	1.2k 1.2×	181 0.3×	319 0.9×	342 1.3×	154	4.8k
Shinji Yamazaki United States	25	1.4k 1.0×	1.2k 1.2×	266 0.5×	141 0.4×	114 0.4×	76	3.0k
Jan H. Beumer United States	40	2.3k 1.7×	2.1k 2.0×	191 0.4×	420 1.2×	476 1.9×	234	4.8k
Cody J. Peer United States	33	1.8k 1.3×	1.5k 1.5×	174 0.3×	172 0.5×	209 0.8×	156	4.0k
Tristan M. Sissung United States	30	1.2k 0.9×	1.4k 1.4×	432 0.8×	116 0.3×	91 0.4×	94	2.9k
Yingli Wu China	32	2.2k 1.6×	516 0.5×	170 0.3×	327 0.9×	94 0.4×	145	3.2k

Countries citing papers authored by Robert A. Parise

Since Specialization

Citations

This map shows the geographic impact of Robert A. Parise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Parise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Parise more than expected).

Fields of papers citing papers by Robert A. Parise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Parise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Parise. The network helps show where Robert A. Parise may publish in the future.

Co-authorship network of co-authors of Robert A. Parise

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Parise. A scholar is included among the top collaborators of Robert A. Parise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Parise. Robert A. Parise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kiesel, Brian F., Jianxia Guo, Robert A. Parise, et al.. (2024). Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice. Cancer Chemotherapy and Pharmacology. 94(2). 271–283. 2 indexed citations

Liu, Haizhou, Hui Liu, Zhiyi Zhou, et al.. (2023). Scutellaria baicalensis enhances 5-fluorouracil-based chemotherapy via inhibition of proliferative signaling pathways. Cell Communication and Signaling. 21(1). 147–147. 8 indexed citations

Thomas, Elizabeth, Puranik Purushottamachar, Jianxia Guo, et al.. (2023). Murine toxicology and pharmacokinetics of lead next generation galeterone analog, VNPP433-3β. Steroids. 192. 109184–109184. 7 indexed citations

Latoche, Joseph D., Robert A. Parise, Jianxia Guo, et al.. (2022). Modular Smart Molecules for PSMA-Targeted Chemotherapy. Molecular Cancer Therapeutics. 21(11). 1701–1709. 11 indexed citations

Leibowitz, Brian J., Liheng Yang, Wei Liang, et al.. (2018). Targeting p53-dependent stem cell loss for intestinal chemoprotection. Science Translational Medicine. 10(427). 42 indexed citations

Kiesel, Brian F., Robert A. Parise, Liza C. Villaruz, et al.. (2017). LC–MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 146. 244–250. 5 indexed citations

Holleran, Julianne L., Julie L. Eiseman, Robert A. Parise, Shivaani Kummar, & Jan H. Beumer. (2016). LC–MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 129. 359–366. 9 indexed citations

Muzzio, Miguel, Julianne L. Holleran, Robert A. Parise, et al.. (2015). Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs. Cancer Chemotherapy and Pharmacology. 75(5). 1015–1023. 2 indexed citations

Heitzer, Marjet D., Teresa T. Liu, Jan H. Beumer, et al.. (2014). VDR Activity Is Differentially Affected by Hic-5 in Prostate Cancer and Stromal Cells. Molecular Cancer Research. 12(8). 1166–1180. 14 indexed citations

10.

Appleman, Leonard J., Sanjeeve Balasubramaniam, Robert A. Parise, et al.. (2014). A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. Clinical Cancer Research. 21(4). 721–729. 5 indexed citations

11.

Parise, Robert A., Jan H. Beumer, Lora H. Rigatti, et al.. (2013). Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Cancer Chemotherapy and Pharmacology. 72(6). 1195–1204. 6 indexed citations

12.

Pillai, Venkateswaran C., Raman Venkataramanan, Robert A. Parise, et al.. (2013). Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer. Drug Metabolism and Disposition. 41(10). 1843–1851. 20 indexed citations

13.

Parise, Robert A., et al.. (2012). Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines. Cancer Chemotherapy and Pharmacology. 71(1). 73–83. 4 indexed citations

14.

Beumer, Jan H., Julie L. Eiseman, Judith A Gilbert, et al.. (2010). Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemotherapy and Pharmacology. 67(2). 421–430. 12 indexed citations

15.

Koon, Henry, Barbara Fingleton, Jeannette Y. Lee, et al.. (2010). Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma. JAIDS Journal of Acquired Immune Deficiency Syndromes. 56(1). 64–68. 47 indexed citations

16.

Zamboni, William C., Julie L. Eiseman, Sandra Strychor, et al.. (2010). Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. Journal of Liposome Research. 21(1). 70–80. 23 indexed citations

17.

Holleran, Julianne L., Robert A. Parise, Merrill J. Egorin, et al.. (2010). Liquid chromatography–tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. Journal of Pharmaceutical and Biomedical Analysis. 52(5). 714–720. 11 indexed citations

18.

Florian, Jeffry, William C. Zamboni, Julie L. Eiseman, et al.. (2006). A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts. Cancer Research. 66. 730–730. 1 indexed citations

19.

Parise, Robert A., Julianne L. Holleran, Jan H. Beumer, Suresh S. Ramalingam, & Merrill J. Egorin. (2006). A liquid chromatography–electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. Journal of Chromatography B. 840(2). 108–115. 52 indexed citations

20.

Parise, Robert A., Ramesh K. Ramanathan, William C. Zamboni, & Merrill J. Egorin. (2002). Sensitive liquid chromatography–mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. Journal of Chromatography B. 783(1). 231–236. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact